PMID- 22713135
OWN - NLM
STAT- MEDLINE
DCOM- 20130311
LR  - 20211203
IS  - 1465-542X (Electronic)
IS  - 1465-5411 (Print)
IS  - 1465-5411 (Linking)
VI  - 14
IP  - 3
DP  - 2012 Jun 19
TI  - BOLERO-2 - will this change practice in advanced breast cancer?
PG  - 311
AB  - The benefit of endocrine therapy has always been limited by the eventual 
      development of acquired resistance. For the first time, clinical research has 
      identified a therapeutic agent, everolimus, that targets the mammalian target of 
      rapamycin (mTOR), which in combination with the aromatase inhibitor exemestane 
      can substantially reduce the risk of disease progression and seemingly circumvent 
      endocrine resistance. The magnitude of the benefit represents a quantum shift in 
      how we should use endocrine therapy in future, and potentially defines a new 
      standard of care in this setting.
FAU - Johnston, Stephen Rd
AU  - Johnston SR
AD  - The Royal Marsden NHS Foundation Trust, Fulham Road, Chelsea, London, SW3 6JJ, 
      UK. stephen.johnston@rmh.nhs.uk
LA  - eng
PT  - Journal Article
DEP - 20120619
PL  - England
TA  - Breast Cancer Res
JT  - Breast cancer research : BCR
JID - 100927353
RN  - 0 (Androstadienes)
RN  - 0 (Aromatase Inhibitors)
RN  - 0 (Immunosuppressive Agents)
RN  - 9HW64Q8G6G (Everolimus)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - NY22HMQ4BX (exemestane)
RN  - W36ZG6FT64 (Sirolimus)
SB  - IM
MH  - Androstadienes/pharmacology/*therapeutic use
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Aromatase Inhibitors/pharmacology/*therapeutic use
MH  - Breast Neoplasms/*drug therapy
MH  - Everolimus
MH  - Female
MH  - Humans
MH  - Immunosuppressive Agents
MH  - Sirolimus/*analogs & derivatives/pharmacology/therapeutic use
MH  - TOR Serine-Threonine Kinases/*antagonists & inhibitors
PMC - PMC3446325
EDAT- 2012/06/21 06:00
MHDA- 2013/03/12 06:00
PMCR- 2012/12/19
CRDT- 2012/06/21 06:00
PHST- 2012/06/21 06:00 [entrez]
PHST- 2012/06/21 06:00 [pubmed]
PHST- 2013/03/12 06:00 [medline]
PHST- 2012/12/19 00:00 [pmc-release]
AID - bcr3126 [pii]
AID - 10.1186/bcr3126 [doi]
PST - epublish
SO  - Breast Cancer Res. 2012 Jun 19;14(3):311. doi: 10.1186/bcr3126.